<table border="1" id="iec15bda1-f43e-41e6-8a48-b1eb5965a4e1" width="715" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>TABLE 2: The Influence of Age, Liver and Kidney Function on the 
Clearance and Terminal Half-life of Ketorolac Tromethamine (IM<sup>1</sup> and Oral<sup>2</sup>) in Adult 
Populations</caption>
<col width="32%"></col>
<col width="16%"></col>
<col width="16%"></col>
<col width="15%"></col>
<col width="19%"></col>
<tbody>
<tr>
<td>
<content stylecode="bold">Types 
of<br/>Subjects</content>
</td>
<td>
<content stylecode="bold">Total 
Clearance<br/>[in L/h/kg]<sup>3</sup>
</content>
</td>
<td>
<content stylecode="bold">Terminal Half-Life<br/>[in 
hours]</content>
</td>
</tr>
<tr>
<td>
<content stylecode="bold">IM<br/>Mean (range)</content>
</td>
<td>
<content stylecode="bold">ORAL<br/>Mean (range)</content>
</td>
<td>
<content stylecode="bold">IM<br/>Mean (range)</content>
</td>
<td>
<content stylecode="bold">ORAL<br/>Mean 
(range)</content>
</td>
</tr>
<tr>
<td>Normal Subjects<br/>IM (n = 54) mean age = 32, range 
= 18 to 60<br/>Oral (n = 77) mean age = 32, <br/>range = 20 to 60</td>
<td>
<br/>0.023<br/>(0.010 to 0.046)</td>
<td>
<br/>0.025<br/>(0.013 to 0.050)</td>
<td>
<br/>5.3<br/>(3.5 to 9.2)</td>
<td>
<br/>5.3<br/>(2.4 to 9)</td>
</tr>
<tr>
<td>Healthy Elderly Subjects<br/>IM (n = 13), Oral (n = 
12)<br/>mean age = 72, range = 65 to 78</td>
<td>0.019<br/>(0.013 to 0.034)<br/>
</td>
<td>0.024<br/>(0.018 to 0.034)<br/>
</td>
<td>7<br/>(4.7 to 8.6)<br/>
</td>
<td>6.1<br/>(4.3 to 7.6)<br/>
</td>
</tr>
<tr>
<td>Patients with Hepatic Dysfunction<br/>IM and Oral (n 
= 7)<br/>mean age = 51, range = 43 to 64</td>
<td>0.029<br/>(0.013 to 0.066)<br/>
</td>
<td>0.033<br/>(0.019 to 0.051)<br/>
</td>
<td>5.4<br/>(2.2 to 6.9)<br/>
</td>
<td>4.5<br/>(1.6 to 7.6)<br/>
</td>
</tr>
<tr>
<td>Patients with Renal Impairment<br/>IM (n = 25), Oral 
( n = 9)<br/>serum creatinine = 1.9 to 5 mg/dL<br/>mean age (IM) = 54, range 35 to 
71<br/>mean age (oral) = 57, range = 39 to 70</td>
<td>0.015<br/>(0.005 to 0.043)</td>
<td>0.016<br/>(0.007 to 0.052)</td>
<td>10.3<br/>(5.9 to 19.2)</td>
<td>10.8<br/>(3.4 to 18.9)</td>
</tr>
<tr>
<td>Renal Dialysis Patients<br/>IM and Oral (n 
=9),<br/>mean age = 40, range = 27 to 63</td>
<td>0.016<br/>(0.003 to 0.036)<br/>
</td>
<td>――<br/>
</td>
<td>13.6<br/>(8.0 to 39.1)<br/>
</td>
<td>――<br/>
</td>
</tr>
<tr>
<td>
<sup>1</sup> 
Estimated from 30 mg single IM doses of ketorolac tromethamine<br/>
<sup>2</sup>Estimated from 10 mg single oral doses of ketorolac 
tromethamine<br/>
<sup>3</sup>Liters/hour/kilogram </td>
</tr>
</tbody>
</table>